XERS vs USAS
Comparison between Xeris Biopharma Holdings Inc (XERS, Company) and Americas Gold and Silver Corp (USAS, Company).
XERS is from the Healthcare sector, while USAS is from the Basic Materials sector.
5-Year PerformanceXERS has outperformed USAS, delivering a return of +20.1% compared to +4.1%
XERS vs USAS - Performance Comparison
Key Characteristics
Financial metrics and valuation ratios
XERS vs USAS - Historical Returns
Returns include dividend reinvestment.
XERS vs USAS - Annual Returns (2016 - 2026)
Returns include dividend reinvestment.
| Year | XERS | USAS |
|---|---|---|
| 2026 | +14.42% | -20.55% |
| 2025 | +126.88% | +424.10% |
| 2024 | +49.67% | +52.07% |
| 2023 | +109.82% | -58.36% |
| 2022 | -52.67% | -30.69% |
| 2021 | -44.82% | -76.07% |
| 2020 | -26.57% | +2.87% |
| 2019 | -59.71% | +87.57% |
| 2018 | -15.92% | -59.46% |
| 2017 | N/A | +29.44% |
| 2016 | N/A | +4.59% |
XERS vs USAS Drawdown Comparison
The maximum drawdown for XERS was -96.22%, occurring on Jan 5, 2023. This drawdown has not yet recovered.
The maximum drawdown for USAS was -95.85%, occurring on Mar 15, 2024. This drawdown has not yet recovered.
The current XERS drawdown is -69.11%. The current USAS drawdown is -66.86%.
| Rank | XERS | USAS |
|---|---|---|
| #1 | -96.22% Sep 10, 2018 - Jan 5, 2023 | -95.85% Sep 7, 2017 - Mar 15, 2024 |
| #2 | -17.12% Jul 24, 2018 - Aug 14, 2018 | -30.33% Feb 21, 2017 - Aug 28, 2017 |
| #3 | -10.98% Jun 21, 2018 - Jul 20, 2018 | -6.07% Jan 17, 2017 - Feb 6, 2017 |
| #4 | -7.87% Aug 14, 2018 - Aug 22, 2018 | -5.77% Jan 5, 2017 - Jan 11, 2017 |
| #5 | -3.41% Aug 23, 2018 - Sep 7, 2018 | -5.25% Feb 6, 2017 - Feb 16, 2017 |
| #6 | -3.07% Jul 20, 2018 - Jul 24, 2018 | -5.14% Dec 29, 2016 - Jan 3, 2017 |
| #7 | N/A | -1.02% Aug 28, 2017 - Aug 30, 2017 |
| #8 | N/A | -0.29% Aug 31, 2017 - Sep 5, 2017 |
Correlation
Correlation between XERS and USAS is 0.51 which considered as a moderate positive correlation - the stocks show some tendency to move together.
Select Stocks to Compare
More Comparisons
Compare with similar stocks